Brain Scanner Articles & Analysis: Older
18 news found
Approximately 201 patients will be enrolled to study the XPro™ intervention. The objectives of this study are to determine the safety, tolerability, and efficacy of XPro™ in patients with mild AD. Oxford, UK, 29th March 2022. Oxford Brain Diagnostics, a software company focused on developing diagnostics that identify changes in the brain at a cellular level, today announced that ...
PARIS, FRANCE, March 3, 2022, PRNewswire – Qynapse SAS, a medical technology company commercializing an FDA approved/CE cleared AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to announce that a symposium oral presentation and a poster presentation will be delivered at the upcoming AD/PD™ 2022 International Conference on ...
ByQynapse
BOSTON, MA, February 14, 2022, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to present 2 posters at the annual Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum 2022, on February 24-26, in West Palm Beach, FL. The posters ...
ByQynapse
BOSTON, MA, November 22, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an artificial intelligence (AI)-powered neuroimaging software platform for central nervous system (CNS) disorders, will unveil its new brand and latest AI developments as a key exhibitor in the AI Showcase at the 107th Radiology Society of North America (RSNA) Annual Meeting, from ...
ByQynapse
BOSTON, MA, November 4, 2021, PRNewswire – Qynapse Inc., a medical technology company commercializing an AI-powered neuroimaging software platform for central nervous system (CNS) disorders, is pleased to sponsor the 14th Clinical Trials on Alzheimer’s Disease conference (CTAD) to be held from November 9-12, 2021, in Boston, MA. Qynapse will present new results on Qypredict®, ...
ByQynapse
Manus Neurodynamica Limited (“Manus”), who develop and market products and technologies for neuromotor assessment, will be joining the ABHI UK Pavilion at MEDICA 2021 (15 – 18 November 2021) to launch their revolutionary non-invasive technology that supports an earlier and more accurate diagnosis of dementias and cognitive impairment. The NeuroMotor Pen (NMP) is a unique, ...
Clinical trial underway at five US hospital sites to evaluate Sense’s novel, non-invasive brain scanner to monitor intracranial hemorrhage in acute hospital setting Drug Controller General of India (DCGI) and Health Canada grant permission to conduct clinical trial at multiple sites in India and Canada Current standard of care lacks a means to monitor ...
In Japan, clinical MRI scanners are available for the diagnosis and evaluation of dementia. Brain imaging by MRI is available for patients with dementia and the prodromal stages using standard health insurance. ...
(August 17, 2021—Montreal, Canada and Cincinnati, Ohio) LOK Corporation, a manufacturing agent that helps companies develop and manage their international distribution network and Sense Neuro Diagnostics, a medical technology company focused on improving outcomes for stroke and brain injury patients today announced a commercial partnership to bring innovative ...
Axial3D is delighted to be working in partnership with NeuroNav to improve the neurosurgical navigation workflow using artificial intelligence (AI). Neurosurgery procedures are extremely complex requiring high precision to avoid damage to vital structures of the brain. Neuronavigation systems help to guide surgeons to perform an even more accurate surgery, decreasing the percentage of serious ...
ByAxial3D
More than 400,000 military personnel have suffered at least one traumatic brain injury in the last two decades. Long-term consequences for patients may have been better if doctors could more quickly have diagnosed the situation and treated it. Now there appears to be a solution and it involves the Norwood company Sense Neuro Diagnostics. ...
Department of Defense will accelerate development of a new rapid, noninvasive brain scanner that can detect and continuously monitor traumatic brain injury in a battlefield or field environment. ...
” Each year nearly 800,000 people suffer strokes in the United States and 1.7 million Americans suffer traumatic brain injury. Ongoing or repeat bleeding in the brain contributes to decreased brain function and disability and may be difficult to detect under the current standard of care. There is currently no objective way to detect ...
Oxford Brain Diagnostics Ltd, a software company focused on developing diagnostics based on changes in the brain at the cellular level, is delighted to announce that we have been awarded funding by the National Institute for Health Research (NIHR) to assess CDM® as a novel and promising tool to identify and predict disease progression amongst patients presenting with mild cognitive impairment ...
And ultrasensitive sensors that exploit quantum processes will set the stage for such applications as wearable brain scanners and vehicles that can see around corners. These and the other emerging technologies have been singled out by an international steering group of experts. ...
Oxford Brain Diagnostics Ltd, a spinout from the University of Oxford specialising in the measurement of neurodegeneration in Alzheimer’s disease, today announces that the US Food and Drug Administration (FDA) has awarded Breakthrough Device Designation to its Cortical Disarray Measurement (CDM®) Software Device for evaluating adults at risk of Alzheimer’s disease Oxford Brain ...
NEWPORT BEACH, CA, USA, May 7, 2020 /EINPresswire.com/ — Evoke Neuroscience announced today that IBM Master Inventor, United Nations Artificial Intelligence (AI) Subject Matter Expert, and UC Irvine Professor Neil Sahota has joined the company’s executive advisory board. For the past 20 years, Neil has worked with Global Fortune 500 companies and world government leaders to foster ...
They will jointly conduct research to understand design and application issues involved in the use of a dedicated MRI brain scanner to image for a range of neurological and psychiatric disorders such as stroke, Alzheimer’s Disease, Parkinson’s Disease, traumatic brain disorder (TBI), depression, and autism. ...
ByGE Power